Quarterly net revenues of $69.7 million, representing 30 percent growth versus the fourth quarter 2017 and 8 percent growth versus the third quarter 2018 Full year 2018 net revenues of $248.1 million, representing annual growth of 40 percent compared to 2017 Three additional phase 3 clinical trials ongoing studying the use of Optune in brain …

Full year 2018 preliminary net revenues of $248.0 million, representing annual growth of more than 40 percent compared to 2017 Fourth quarter and full year 2018 financial results to be reported Thursday, Feb. 28, 2019 ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to present at 2:30 p.m. PST. A live audio webcast …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce four inaugural Tumor Treating Fields research grants. The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to …

Patients who used Optune more than 90 percent of the time experienced a median overall survival of 24.9 months Monthly usage was a predictor of survival, independent of other prognostic factors such as Karnofsky Performance Score, age, or MGMT methylation status ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the results of a retrospective …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China. The award is part of the BayHelix China Healthcare Awards series, celebrating outstanding individuals and companies for their …

Presentations span 21 research areas with five oral presentations More than 50 presentations from external authors indicate a growing interest Novocure’s proprietary Tumor Treating Fields platform ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced more than 70 presentations on Tumor Treating Fields, including five oral presentations, will be featured at the 23rd Annual Meeting …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will host an investor event with Zai Lab on Nov. 14, 2018, in Shanghai, China. William Doyle, Novocure’s Executive Chairman, Dr. Samantha Du, Zai Lab’s CEO, and Tao Fu, Zai Lab’s President and Chief Operating Officer, will review the strategic collaboration for Tumor Treating …

Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018 Humanitarian device exemption (HDE) application submitted to FDA for approval in malignant pleural mesothelioma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today reported financial results for the three and nine months …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today the retirement of Novocure founder Professor Yoram Palti, MD, PhD, and director Louis J. Lavigne, Jr. from the board of directors effective October 24, 2018. Professor Palti invented Tumor Treating Fields and founded Novocure in 2000. He serves as the company’s Chief Technology Officer (CTO) and …